Humanigen Announces Closing of Public Offering of Common Stock
April 06 2021 - 2:02PM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN)
(“Humanigen”), a clinical stage biopharmaceutical company focused
on preventing and treating an immune hyper-response called
“cytokine storm” with its lead drug candidate lenzilumab™, today
announced that on April 5, 2021 it completed its underwritten
public offering of common stock, resulting in gross proceeds to
Humanigen of approximately $92.5 million. Humanigen intends to use
the net proceeds from the offering for manufacturing and commercial
preparation in the event of receipt of an Emergency Use
Authorization from the Food and Drug Administration for lenzilumab™
in hospitalized COVID-19 patients, as well as for working capital
and other general corporate purposes.
A registration statement relating to
the securities sold in the offering has been declared effective by
the Securities and Exchange Commission (the “SEC”). The securities
were offered only by means of a prospectus supplement and
accompanying prospectus forming a part of the effective
registration statement. A preliminary prospectus supplement and a
final prospectus supplement relating to and describing the terms of
the offering were filed with the SEC and are available on the SEC’s
website located at www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to and
describing the terms of the offering may also be obtained from
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, by e-mail at
prospectus_department@jefferies.com or by telephone at (877)
821-7388; Credit Suisse Securities (USA) LLC, Attention: Prospectus
Department, 6933 Louis Stephens Drive, Morrisville, North Carolina
27650, by email at usa.prospectus@credit-suisse.com or by telephone
at (800) 221-1037; or Cantor Fitzgerald & Co., Attention:
Capital Markets, 499 Park Ave., 6th Floor, New York, New York
10022, by e-mail at prospectus@cantor.com.
This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
any securities, nor shall there be any sale of any securities in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Forward-Looking Statements
This release contains
forward-looking statements. Forward-looking statements reflect
management’s current knowledge, assumptions, judgment and
expectations regarding future performance or events. Although
management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such
expectations will prove to be correct and you should be aware that
actual events or results may differ materially from those contained
in the forward-looking statements. Words such as “will,” “expect,”
“intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,”
“continue,” and similar expressions identify forward-looking
statements. Examples of forward-looking statements in this release
include, without limitation, statements regarding the contemplated
use of proceeds. Forward-looking statements are subject to a number
of risks and uncertainties including, but not limited to, the
various risks and uncertainties described in the “Risk Factors”
sections and elsewhere in the Company's periodic and other filings
with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not place undue
reliance on any forward-looking statements, which speak only as of
the date of this release. We undertake no obligation to revise or
update any forward-looking statements made in this press release to
reflect events or circumstances after the date hereof or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210406005985/en/
Humanigen Media Grace Catlett RXMD Gcatlett@rxmedyn.com
516-318-8563
Humanigen Investors Alan Lada Solebury Trout
ALada@SoleburyTrout.com 617-221-8006
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024